About Hainan Poly Pharm Company

The company (stock code: 300630) was founded in 1992 to open up the entire pharmaceutical manufacturing industry chain and form the integration of key intermediates, APIs and formulations. Based on pharmaceutical production quality management standards such as the US FDA, EU EMA, WHO, and China NMPA, etc., the company continues to improve pharmaceutical production process levels and quality control capabilities, intelligent pharmaceutical manufacturing and automated production capabilities, and build production bases for APIs, solid preparations and injections with a high quality management level. The company is a high-tech enterprise specializing in drug research and development, registration, production and sales. The products sold by the company are mainly prescription drugs, covering anti-allergic drugs, non-steroidal analgesic and anti-inflammatory drugs, antibiotics, digestive drugs, etc., cardiovascular drugs, contrast agents, first-aid drugs, etc. field. Company honors: The “Development and production transformation of sodium diclofenac enteric sustained-release capsules” project won the second prize of science and technology in Hainan Province, the “development and industrialization of desloratadine dry suspensions” project won the third prize of science and technology in Hainan Province, “Fubiding (desloratadine dry suspension)” was rated as an excellent product in the pharmaceutical industry in Hainan Province by the Hainan Pharmaceutical Industry Association. Desloratadine dispersion tablets and desloratadine dry pharmaceutical suspensions won the Chinese brand at the “28th National Pharmaceutical Economic Information Conference” · 2016 Hospital terminal and primary terminal brand list (anti-allergic drug category), pharmaceutical industry 13th Five-Year “Enterprise Management Award”.